Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1092 | 975 | 1215 | 1068 | 1268 | - |
Fund Return | 9.17% | -2.54% | 21.5% | 2.23% | 4.86% | - |
Place in category | 582 | 1504 | 498 | 1278 | 1191 | - |
% in Category | 24 | 72 | 20 | 69 | 78 | - |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
IGlobal Franchise Fund A EUR Acc | 8.54B | 6.14 | 2.39 | 9.68 | ||
Investec Glbl Strat EM EqI Acc EUR | 1.68B | 15.35 | 0.40 | 4.64 | ||
Invec GlblStrat GlblStratEqA AccEUR | 1.46B | 18.36 | 4.49 | 8.70 | ||
Invec GlblStratGlblStratEqS Inc EUR | 1.46B | 20.17 | 6.33 | 10.64 | ||
Investec Global Strategy Fund Euroa | 490.64M | 9.83 | 3.00 | 5.93 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
European Growth Fund A Acc EUR | 156.66M | 12.55 | 4.13 | 5.59 | ||
European Growth Fund E Acc EUR | 20.53M | 11.84 | 3.35 | 4.80 | ||
European Growth Fund Y Acc EUR | 142.8M | 13.30 | 5.02 | 6.46 | ||
European Growth Fund Y DIST EUR | 63.55M | 13.33 | 5.02 | 6.47 | ||
European Growth Fund A DIST Eue | 6.46B | 12.54 | 4.13 | 5.59 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Novo Nordisk B | DK0062498333 | 5.76 | 756.0 | +0.95% | |
ASML Holding | NL0010273215 | 5.54 | 627.70 | -0.41% | |
SAP | DE0007164600 | 4.98 | 219.450 | -0.43% | |
Barclays | GB0031348658 | 3.11 | 258.85 | +0.52% | |
AstraZeneca | GB0009895292 | 3.07 | 10,144.0 | +1.54% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Strong Sell | Neutral | Buy |
Technical Indicators | Strong Sell | BUY | Strong Buy |
Summary | Strong Sell | Neutral | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review